Heart transplant patients may get safer virus protection

NCT ID NCT07079735

Recruiting now Disease control Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a newer drug, letermovir, is safer and more effective than the standard valganciclovir for preventing CMV infection in heart transplant recipients. About 150 moderate- to high-risk adults will be enrolled. The main focus is on reducing side effects like low white blood cell counts while still preventing the virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Letermovir and valganciclovir (antiviral drugs)
What this could lead to: If letermovir works better with fewer side effects, it could become the new standard for preventing CMV in heart transplant patients.
What could go wrong: This is a mid-stage trial with only 150 participants, so results may not apply to everyone. Both drugs have known side effects like low white blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMV VIREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Rejection, Psychology transplant rejection cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CMV VIREMIA HEART TRANSPLANT FAILURE AND REJECTION HEART TRANSPLANT INFECTION

Contacts and locations

Locations

Columbia University/NYP Milstein Hospital
RECRUITING

New York, New York, 10032, United States
NYP-Weill Cornell
RECRUITING

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.